Short-term pain, long-term gain

Another step-up in Peruvian volumes

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold 40,000 shares at 450.528DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Still cheap and the Red Sea is still closed

A. P. Møller Mærsk (Sell, TP: DKK9400.00) - Resistance to gravity seem...

The Q1 report was largely as expected, albeit with support in the results related to mostly passing effects. Hence, we retain our view that the chronic oversupply of vessels will deteriorate the current value of the company. On rates converging towards 2016 levels, it should burn through more than USD13bn by the end of our forecast period, with no respite in sight due to the towering orderbook and owners still willing to order. We reiterate our SELL, but have raised our target price to DKK9,400 ...

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

Q1'25 beat driven by Ocean and Terminals

Sampo Oyj (Buy, TP: EUR10.20) - Strong underwriting momentum

Although Q1 PTP declined by 19% YOY to EUR377m, due to a lower investment result, Sampo continued to see strong underwriting momentum, with 9% YOY GWP growth (in local FX) and a 2.5%-points stronger underlying combined ratio YOY. Based on a better synergy outlook from the integration of Topdanmark, it increased its cost improvement guidance. We have raised our 2026–2027e EPS by ~1% on higher growth and ongoing underwriting improvements. We have raised our target price to EUR10.2 (9.8), and reite...

Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead

Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.

A. P. Møller Mærsk (Sell, TP: DKK8800.00) - Overcapacity at the gates

We find the recent share price strength surprising and likely short-lived due to a challenging supply/demand balance, only augmented by the escalating trade tensions. While we expect a Q1 beat versus consensus, we believe the company’s outlook is unlikely to satisfy buy-side expectations, and we see sizeable downside risk to the current valuation. We reiterate our SELL and have cut our target price to DKK8,800 (10,800).

Tariffs will hurt, but cons. is too low for Q1

E-commerce traffic - April 2025

Seafood - Fat Trout Weekly

Seafood - Fat Trout Weekly

Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales

We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.

Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression

We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).

Seafood - Chilean biomass update

Seafood - Chilean biomass update

Sweden's preferred beauty retailer

Seafood - Fat Trout Weekly

Seafood - Fat Trout Weekly

Suppliers see the beauty

Seafood - Norwegian biomass update

Seafood - Norwegian biomass update